U.S. flag An official website of the United States government
  1. Home
  2. Vaccines, Blood & Biologics
  3. Cellular & Gene Therapy Products
  4. BREYANZI (lisocabtagene maraleucel)
  1. Cellular & Gene Therapy Products

BREYANZI (lisocabtagene maraleucel)

STN# BLA 125714
Proper Name: lisocabtagene maraleucel
Tradename: BREYANZI
Manufacturer: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company


  • For treatment of adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B, who have:
    • Refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy; or
    • Refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplantation (HSCT) due to comorbidities or age; or
    • Relapsed or refractory disease after two or more lines of systemic therapy.
  • Limitations of Use: BREYANZI is not indicated for the treatment of patients with primary central nervous system lymphoma

Product Information

Supporting Documents

Back to Top